N-((2R,3R)-3-hydroxy-1-(pyrrolidin-1-yl)pent-4-yn-2-yl)palmitamide | 906528-79-8

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: N-((2R,3R)-3-hydroxy-1-(pyrrolidin-1-yl)pent-4-yn-2-yl)palmitamide
• 英文别名: N-[(2R,3R)-3-hydroxy-1-pyrrolidin-1-ylpent-4-yn-2-yl]hexadecanamide
• CAS: 906528-79-8
• 化学式: C₂₅H₄₆N₂O₂
• 分子量: 406.652
• InChiKey: AFRQXEOGIHYZQA-DNQXCXABSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.9
• 重原子数：
  29
• 可旋转键数：
  18
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  52.6
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  N-((2R,3R)-3-hydroxy-1-(pyrrolidin-1-yl)pent-4-yn-2-yl)palmitamide 在 bis-triphenylphosphine-palladium(II) chloride 哌啶 、 红铝 作用下， 以 乙醚 为溶剂， 生成 (E,3R,4R)-1-(hexadecylamino)-1-phenyl-5-(pyrrolidin-1-yl)pent-1-en-3-ol
  参考文献：
  名称：

  Synthesis and biological evaluation of novel PDMP analogues

  摘要：

  A new series of hybrid PDMP analogues, based both on PDMP and styryl analogues of natural ceramide, has been synthesized from D-serine. The synthetic route was developed such that future introduction of different aryl groups is straightforward. Biological evaluation, both in vitro on rat liver Golgi fractions as well as in HEK-293 and COS-7 cells, revealed two lead compounds with comparable inhibitory potency as PDMP, which could be elaborated to more potent inhibitors. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2006.03.048
• 作为产物：
  描述：

  、 棕榈酸对硝基苯酯 在 吡啶 、 1-羟基苯并三唑 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 48.0h， 以71 mg的产率得到N-((2R,3R)-3-hydroxy-1-(pyrrolidin-1-yl)pent-4-yn-2-yl)palmitamide
  参考文献：
  名称：

  Synthesis and biological evaluation of novel PDMP analogues

  摘要：

  A new series of hybrid PDMP analogues, based both on PDMP and styryl analogues of natural ceramide, has been synthesized from D-serine. The synthetic route was developed such that future introduction of different aryl groups is straightforward. Biological evaluation, both in vitro on rat liver Golgi fractions as well as in HEK-293 and COS-7 cells, revealed two lead compounds with comparable inhibitory potency as PDMP, which could be elaborated to more potent inhibitors. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2006.03.048